ORYZON Reports Financial Results and Corporate Update

for the 1st Half Ended June 30, 2018

NET PROFIT OF $ 0.65 M (+$0.02 per share)

MADRID, SPAIN and CAMBRIDGE, MA, July 30, 2018 – Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the first half of 2018 and provided an update on the Company's recent developments.

R&D investments of € 3.7 million during the first half of 2018 have permitted Oryzon to significantly advance its clinical portfolio. The most significant one has been the CTA approval from the Medicines Regulatory Agencies in Spain, France and the United Kingdom to start ETHERAL, a Phase IIa clinical trial in patients with mild and moderate Alzheimer's disease treated with VAFIDEMSTAT (ORY-2001). The recruitment of the first patients in the period has been also announced.

The company has worked intensively this second quarter to finalize the preparations of two new Phase IIa clinical trials of IADADEMSTAT (ORY-1001) in Acute Myeloid Leukemia and in Small Cell Lung Cancer, after regaining from Roche all the rights of the molecule without cost at the end of last January. The company has already filed the corresponding CTA authorizations to Regulatory Agencies to carry out these new PhIIa studies in leukemia and small cell lung cancer, and will inform about its regulatory approval and the operational start thereof in due time. At the end of the quarter, a relevant scientific article was published by the company's scientists in the March issue of Cancer Cell. The article, entitled "ORY-1001, a potent and selective covalent inhibitor of KDM1A, for the treatment of acute leukemia", has been published in collaboration with scientists from the Cancer Research UK Manchester Institute (UK), the Weill University, Cornell in New York (USA) and the Gustave Roussy Hospital in Paris (France) and details that the pharmacological inhibition of KDM1A with therapeutic doses of ORY-1001 produces the differentiation of cancer cells while respecting normal cells at the same time.

The additional clinical development of VAFIDEMSTAT (ORY-2001) also follows its course. The Phase IIa clinical trial in Multiple Sclerosis (MS), called SATEEN, recruited its first patient during the month of January and has continued the recruitment during the second quarter.

There has also been progress in new preclinical experiments with VAFIDEMSTAT (ORY-2001) and in the characterization of the Mechanism of Action in other indications in diseases of the Central Nervous System that the company considers may be a relevant option in the clinical development of the drug. Among them we can mention the treatment of behavioral alterations present in patients with diseases such as border line personality disorder, autistic syndrome, ADHD, depression and others. These data can significantly expand the potential clinical development of ORY-2001 beyond the current indications of AD and MS in which the company is currently advancing clinically. Along these lines the company has

filed a CTA request at the Spanish Medicines Agency (AEMPS) to start REIMAGINE: an exploratory basket trial to assess VAFIDEMSTAT (ORY-2001) to treat aggression in patients with three types of psychiatric diseases and two types of neurodegenerative diseasesThe company will inform about its regulatory approval and the operational start of this trial in due time.

The company's third LSD1 inhibitor , ORY-3001, in preclinical phase for non-oncological indications, has successfully completed the regulatory toxicology necessary to obtain the permits to start clinical studies.

In addition, progress has been made in programs in earlier phases.

In summary, the company has two epigenetic experimental molecules "first-in-class" in a set of Phase IIa clinical trials in humans and a third that has completed the regulatory preclinical.

Second Quarter Highlights

- In APRIL 2018 ORYZON receives approval to start ETHERAL: a Phase IIa clinical trial in Alzheimer's Disease with ORY-2001
- In MAY 2018 ROTH Capital initiates equity research and sets the Company Target Price at € 15 per share
- In MAY 2018 ORYZON receives approval in France and in United Kingdom to start ETHERAL: a Phase IIa clinical trial in Alzheimer's Disease with ORY-2001
- In MAY 2018 ORYZON announces First Patients In ETHERAL: a Phase IIa clinical trial in Alzheimer's Disease with ORY-2001
- In JUNE 2018 ORYZON announces First Patients in the UK in ETHERAL: a Phase IIa clinical trial in Alzheimer's Disease with ORY-2001

Financial Update: First Half 2018 Financial Results

Collaboration revenue was $0.00 million for the first 3 and 6 months ended June 30, 2018 and $0.00 and $0.02, million for the first 3 and 6 months ended June, 2017. The 1st half 2017 revenues was the last accrual of the Roche license 2015 milestone.

Research and development (R&D) expenses established themselves at $2.2 and $4.3 million for the first 3 and 6 months ended June 30, 2018 compared to the $1.8 and $3.5 million for the first 3 and 6 months ended June 30, 2017. The $0.8 million increase was driven primarily by accelerated R&D efforts to receive the approval to start ETHERAL - a Phase IIa clinical trial with ORY-2001 in Alzheimer's Disease, – in Spain, France and United Kingdom.

General and administrative expenses were $0.8 and $1.7 million for the first 3 and 6 months ended June 30, 2018 and $1.1 and $2.2 million for the first 3 and 6 months ended June 30, 2017

Net loss of $1.0 and $1.7 million for the first 3 and 6 months ended June 30, 2018 represents an improvement of 28% and 32% compared to the net loss of $1.4 and $2.5 million for the first 3 and 6 months ended June 30, 2017.

Positive Net Result of $0.7 million (+$0.02 per share) for the first 6 months ended June 30, 2018 as a consequence of $3.0 million non-recurrent R&D tax deductions, compared to the negative net result of $3.1 million for the first 6 months ended June 30, 2017 (-$0.10 per share).

Cash, cash equivalents and marketable securities totaled $31.2 million as of June 30, 2018, compared to $42.8 million as of June 30, 2017.

ORYZON GENOMICS SA
BALANCE SHEET DATA (AUDITED)
(Amounts in thousands US $)

	June 30th, 2018	June 30th, 2017
Cash and cash equivalents	30.986	41.493
Marketable securities	165	1.303
Total Assets	68.352	70.932
Deferred revenue	0	0
Total Stockholders' equity	40.697	41.972

ORYZON GENOMICS SA
STATEMENTS OF OPERATIONS (AUDITED)
(US $, amounts in thousands except per share data)

	Three Months Ended June 30		Six Months Ended June 30	
	2018	2017	2018	2017
Collaboration Revenue	0	0	0	19
Operating expenses:				
Research and Development	2.113	1.809	4.321	3.478
General and administrative	838	1.127	1.677	2.159
Total operating expenses	2.950	2.935	5.998	5.637
Loss from Operations	-2.950	-2.935	-5.998	-5.618
Other income, net	1.960	1.545	4.286	3.156
Net Loss	-991	-1.391	-1.712	-2.462
Net Financial & Tax	2.835	-254	2.362	-653
Net Result	1.844	-1.644	650	-3.115
Loss per share allocable to common stockholders:				
Basic	0,11	-0,05	0,02	-0,10
Diluted	0,11	-0,05	0,02	-0,10
Weighted average Shares outstanding				
Basic	33.492.804	32.026.695	33.492.804	30.183.944
Diluted	33.492.804	32.026.695	33.492.804	30.183.944

About Oryzon

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field. Oryzon's LSD1 program has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. The company has offices in Spain and USA. For more information, visit www.oryzon.com.

FORWARD-LOOKING STATEMENTS

This communication contains forward-looking information and statements about Oryzon Genomics, S.A., including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates" and similar expressions. Although Oryzon Genomics, S.A. believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon Genomics, S.A. shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon Genomics, S.A., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon Genomics, S.A. to the Comisión Nacional del Mercado de Valores, which are accessible to the public. Forward-looking statements are not guarantees of future performance. The auditors of Oryzon Genomics, S.A, have not reviewed them. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon Genomics, S.A. or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon Genomics, S.A. on the date hereof. Except as required by applicable law, Oryzon Genomics, S.A. does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States. The Company's securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of the Company's securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company or the selling security holder, as applicable, that will contain detailed information about the Company and management, as well as financial statements.

US Contact:
The Trout Group
Thomas Hoffmann
+1 646 378 2932
thoffmann@troutgroup.com

Spain:
ATREVIA
Patricia Cobo/Luis Rejano
+34 91 564 07 25
pcobo@atrevia.com
lrejano@atrevia.com

The Company:
Emili Torrell
BD Director
+34 93 515 13 13
etorrell@oryzon.com